Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $25.00 by Analysts at Bank of America

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective dropped by Bank of America from $28.00 to $25.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s target price points to a potential upside of 100.00% from the stock’s previous close.

A number of other research analysts have also recently commented on DAWN. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $35.86.

Day One Biopharmaceuticals Stock Up 2.5 %

NASDAQ:DAWN traded up $0.30 during trading hours on Tuesday, hitting $12.50. 290,853 shares of the company traded hands, compared to its average volume of 723,660. The company has a market cap of $1.26 billion, a PE ratio of -12.14 and a beta of -1.46. The firm’s 50-day simple moving average is $13.63 and its 200-day simple moving average is $14.01. Day One Biopharmaceuticals has a one year low of $11.94 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same period in the prior year, the firm posted ($0.54) EPS. As a group, equities research analysts expect that Day One Biopharmaceuticals will post -0.88 EPS for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $16.10, for a total transaction of $161,000.00. Following the completion of the transaction, the insider now owns 1,057,535 shares of the company’s stock, valued at $17,026,313.50. This represents a 0.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders sold 51,745 shares of company stock worth $748,567. 8.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DAWN. Renaissance Technologies LLC purchased a new position in shares of Day One Biopharmaceuticals in the 2nd quarter worth about $994,000. Hsbc Holdings PLC purchased a new position in shares of Day One Biopharmaceuticals in the second quarter worth approximately $163,000. Ally Bridge Group NY LLC purchased a new stake in Day One Biopharmaceuticals during the second quarter valued at approximately $7,387,000. Marshall Wace LLP raised its position in Day One Biopharmaceuticals by 20.1% in the second quarter. Marshall Wace LLP now owns 161,129 shares of the company’s stock worth $2,220,000 after acquiring an additional 26,958 shares during the period. Finally, Point72 DIFC Ltd purchased a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter worth $124,000. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.